论文部分内容阅读
目的探讨蚓激酶胶囊在急性脑梗死治疗中的临床应用效果。方法 2010年1月至2013年1月收治的240例脑梗死患者,按数字表法随机分为对照组和治疗组,每组120例,对照组给予对症常规治疗,治疗组在对照组基础上联合蚓激酶胶囊治疗,2个疗程后对比2组综合疗效及神经功能缺损(NIHSS)情况。结果治疗组总有效率为96.67%,对照组总有效率为75.00%,治疗组的总有效率显著高于对照组(χ2=23.1639,P<0.01)。治疗1个疗程后,治疗组患者的NIHSS评分显著低于对照组(t=2.0951,P<0.05);治疗2个疗程后,治疗组患者的NIHSS评分极显著低于对照组(t=5.6362,P<0.01)。结论蚓激酶胶囊治疗脑梗死可降低神经功能缺损程度,有助于改善患者预后,具有很高的临床应用价值。
Objective To investigate the clinical effect of lumbrokinase capsules in the treatment of acute cerebral infarction. Methods A total of 240 patients with cerebral infarction who were admitted from January 2010 to January 2013 were randomly divided into control group and treatment group according to the digital table method, with 120 cases in each group. The control group was given symptomatic routine treatment. The treatment group was based on the control group Joint Lumbrokinase capsule treatment, after 2 courses of contrast the two groups of comprehensive efficacy and neurological deficit (NIHSS) situation. Results The total effective rate was 96.67% in the treatment group and 75.00% in the control group. The total effective rate in the treatment group was significantly higher than that in the control group (χ2 = 23.1639, P <0.01). After one course of treatment, the NIHSS score of the treatment group was significantly lower than that of the control group (t = 2.0951, P <0.05). After two courses of treatment, the NIHSS score of the treatment group was significantly lower than that of the control group (t = 5.6362, P <0.01). Conclusion Lumbukinase capsules can reduce the degree of neurological deficits and improve the prognosis of patients with cerebral infarction, which has a high clinical value.